Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.
2.

Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.

Gladman DD; ACCLAIM Study Investigators., Sampalis JS, Illouz O, Guérette B.

J Rheumatol. 2010 Sep;37(9):1898-906. doi: 10.3899/jrheum.100069. Epub 2010 Jul 1.

3.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group..

Arthritis Rheum. 2005 Oct;52(10):3279-89.

4.

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.

Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB.

Curr Med Res Opin. 2010 Oct;26(10):2385-92. doi: 10.1185/03007995.2010.515804.

PMID:
20831455
5.

Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.

Strand V, Schett G, Hu C, Stevens RM.

J Rheumatol. 2013 Jul;40(7):1158-65. doi: 10.3899/jrheum.121200. Epub 2013 Apr 15.

PMID:
23588944
6.

Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.

Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.

J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1.

7.

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.

Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, Beutler A, Guzzo C, Gladman D.

Ann Rheum Dis. 2006 Apr;65(4):471-7. Epub 2005 Aug 11.

8.

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH; M02-570 Study Group..

J Rheumatol. 2007 May;34(5):1040-50. Epub 2007 Apr 15. Erratum in: J Rheumatol. 2007 Jun;34(6):1439.

PMID:
17444593
9.

Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.

Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF.

J Rheumatol. 2010 Jun;37(6):1221-7. doi: 10.3899/jrheum.091093. Epub 2010 Apr 15.

10.

Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.

Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, Mack M, Tandon N, Han C, Mease P.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1666-73. doi: 10.1002/acr.22044.

11.

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.

Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP.

Arthritis Rheum. 2007 Aug 15;57(6):1050-7.

12.

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894.

PMID:
18853973
13.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

J Dermatolog Treat. 2007;18(6):341-50.

PMID:
18058494
14.
15.

Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.

J Rheumatol. 2008 Jan;35(1):20-30. Epub 2007 Nov 15.

PMID:
18050385
17.

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.

Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1436-43. doi: 10.1111/j.1468-3083.2011.04308.x. Epub 2011 Oct 31.

PMID:
22035157
18.
19.

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.

Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.

20.

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).

Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr; ATLAS Study Group..

J Rheumatol. 2008 Jul;35(7):1346-53. Epub 2008 May 15. Erratum in: J Rheumatol. 2011 Apr;38(4):788.

PMID:
18484692

Supplemental Content

Support Center